Bolt Biotherapeutics Inc (NAS:BOLT)
$ 0.635 -0.0068 (-1.06%) Market Cap: 24.30 Mil Enterprise Value: -30.25 Mil PE Ratio: 0 PB Ratio: 0.28 GF Score: 37/100

Bolt Biotherapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 09, 2022 / 06:00PM GMT
Release Date Price: $3.39 (+2.73%)
Michael Schmidt
Guggenheim Partners - Analyst

Hello and welcome. My name is Michael Schmidt. I am the Senior Biotech Analyst with Guggenheim Securities. It is my great pleasure to welcome the Bolt Biotherapeutics team. With us today, we have Randy Schatzman, CEO, as well as Edith Perez, Chief Medical Officer. Welcome, and thanks for joining us today.

Randy Schatzman
Bolt Biotherapeutics, Inc. - CEO

Thanks. Pleasure to be with you, Michael. Thanks for having us joining.

Questions & Answers

Michael Schmidt
Guggenheim Partners - Analyst

So, we'll jump right into questions as we have done before, Randy. You know, just starting out with the big picture one, I guess, coming out of 2021, heading into 2022, what should investors be watching out for with Biotherapeutics as the pipeline is advancing?

Randy Schatzman
Bolt Biotherapeutics, Inc. - CEO

Yes, appreciate that. As you can imagine, 2022 for us is going to be a very busy year, both bringing our lead agent, BDC

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot